Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76–78].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [76]
In the citing paper
“coordinate the function of the immune system via the production of chemokines and cytokines, although it should be noted that there is heterogeneity in the cytokines produced by different fibroblasts16–20.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“However, the situation with tumour necrosis factor (TNF) produced by CAFs is more nuanced; the tumour-promoting immunosuppressive activity of FAP+ fibroblasts is associated with suppression of TNF signalling, yet TNF is also able to drive fibroblast activation in certain contexts16,124,125.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
In the citing paper
“Interference with the action of CXCL12 produced by CAFs promotes T cell-mediated tumour control16,121,122”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [16]
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994
Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7235 · Cited by 748
Cited by
Items 301–400 of 1,000
Pancreatic cancer microenvironment: a current dilemma
Uzunparmak, B., & Şahin, İ. H. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0221-1 · Cited by 105
“Carcinoma-associated fibroblasts have also been linked to downregulation of anti-cancer immune response [52].”
BackgroundInvolvement of local renin‐angiotensin system in immunosuppression of tumor microenvironment
Nakamura, K., Yaguchi, T., Ohmura, G., Kobayashi, A., Kawamura, N., Iwata, T., Kiniwa, Y., Okuyama, R., & Kawakami, Y. (2017) · Cancer Science · doi:10.1111/cas.13423 · Cited by 100
“Although most reports have been based on in vitro experiments using cultured and expanded CAF, a recent study using genetically engineered mouse models where CAF were depleted, showed that CAF were directly involved in decreased antitumor CD8 T-cell responses.(43,44) CAF also produce CXCL12, which has been shown to in…”
BackgroundTherapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells.
Huang, T., Guan, X., & Fu, L. (2019) · Europe PMC (PubMed Central) · Cited by 109
Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro
Teichgräber, V., Monasterio, C., Chaitanya, K., Boger, R. J., Gordon, K., Dieterle, T., Jäger, D., & Bauer, S. (2015) · Advances in Medical Sciences · doi:10.1016/j.advms.2015.04.006 · Cited by 102
“FAP-expressing stromal cells have been shown to suppress antitumor immunity, adding another layer of functionality to FAP that could contribute to tumor progression [25].”
BackgroundOpzoomer, J. W., Anstee, J. E., Dean, I., Hill, E. J., Bouybayoune, I., Caron, J., Muliaditan, T., Gordon, P., Sosnowska, D., Nuamah, R. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg9518 · Cited by 96
Self-citationTruffi, M., Mazzucchelli, S., Bonizzi, A., Sorrentino, L., Allevi, R., Vanna, R., Morasso, C., & Corsi, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061263 · Cited by 94
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 99
Pancreatic cancer: The microenvironment needs attention too!
Apte, M. V., Xu, Z., Pothula, S. P., Goldstein, D., Pirola, R. C., & Wilson, J. S. (2015) · Pancreatology · doi:10.1016/j.pan.2015.02.013 · Cited by 104
“In addition, it is postulated that fibroblast activation protein-a (FAP-a) secreted by PSCs, can also disrupt anti-tumour immunity, since depletion of FAP-a þve cells allows immune response-associated tumour regression [29].”
BackgroundBockorny, B., Macarulla, T., Semenisty, V., Borazanci, E., Feliu, J., Ponz-Sarvise, M., Abad, D. G., Oberstein, P., Alistar, A., Muñoz, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0929 · Cited by 92
Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 102
Donelan, W., Dominguez‐Gutierrez, P. R., & Kusmartsev, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971278 · Cited by 93
Liao, Y., Ni, Y., Ren, H., Liu, W., & Du, J. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1471-8 · Cited by 92
Host Indoleamine 2,3-Dioxygenase: Contribution to Systemic Acquired Tumor Tolerance
Johnson, T. S., & Munn, D. H. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.689405 · Cited by 107
“…and truly foreign “neo”-antigens (Willimsky and Blankenstein, 2005; Zhang et al., 2007; Calzascia et al., 2008; Peggs et al., 2008; Quezada et al., 2008; Clark et al., 2009; Darrasse-Jeze et al., 2009; Kraman et al., 2010; Schreiber and Rowley, 2010; Quezada et al., 2011; Schreiber et al., 2011).”
Bušek, P., Balážiová, E., Matrasová, I., Hilser, M., Tomáš, R., Syrůček, M., Zemanová, Z., Krepela, E., Běláček, J., & Šedo, A. (2016) · Tumor Biology · doi:10.1007/s13277-016-5274-9 · Cited by 92
Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment
Lin, Y., Li, B., Yang, X., Cai, Q., Liu, W., Tian, M., Luo, H., Yin, W., Song, Y., Shi, Y., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.005 · Cited by 85
Li, J., Chen, K., Liu, H., Cheng, K., Yang, M., Zhang, J., Cheng, J. D., Zhang, Y., & Cheng, Z. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300278r · Cited by 88
Krueger, T. E. G., Thorek, D. L. J., Meeker, A. K., Isaacs, J. T., & Brennen, W. N. (2018) · The Prostate · doi:10.1002/pros.23738 · Cited by 93
Cioffi, M., Trabulo, S. M., Vallespinos, M., Raj, D., Bou Kheir, T., Lin, M.-L., Begum, J., Baker, A.-M., Amgheib, A., Saif, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15450 · Cited by 87
Cheng, H.-W., Onder, L., Cupovic, J., Boesch, M., Novkovic, M., Pikor, N., Tarantino, I., Rodriguez, R., Schneider, T., Jochum, W., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.12.998 · Cited by 89
Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment
Comen, E. A., Bowman, R. L., & Kleppe, M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00056 · Cited by 99
“Additionally, while one of the primary functions of fibroblasts in wound healing is to recruit immune cells, CAFs have been shown to negatively regulate immune responses in a TNFα and IFNγ dependent manner (Kraman et al., 2010).”
BackgroundBlair, A. B., Kim, V. M., Muth, S. T., Saung, M. T., Lokker, N. A., Blouw, B., Armstrong, T. D., Jaffee, E. M., Tsujikawa, T., Coussens, L. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4192 · Cited by 90
“Previously, it was shown that depleting stromal fibroblasts by targeting fibroblast activation protein-a (FAP) enhances antitumor immunity (39).”
BackgroundEffects of Radiation on the Tumor Microenvironment
Monjazeb, A. M., Schalper, K. A., Villarroel‐Espíndola, F., Nguyen, A. T., Shiao, S. L., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.004 · Cited by 93
Knops, A. M., South, A. P., Rodeck, U., Martinez‐Outschoorn, U., Harshyne, L. A., Johnson, J. M., Luginbuhl, A., & Curry, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.565306 · Cited by 96
Song, H., Lü, T., Han, D., Zhang, J., Gan, L., Xu, C., Liu, S., Li, P., Zhang, K., Hu, Z., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0932 · Cited by 100
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 83
“In contrast, in experiments where FAP+ fibroblasts were depleted, improved outcomes were observed in mouse models of PDAC [130, 131].”
ResultLiver Tropism in Cancer: The Hepatic Metastatic Niche
Mielgo, A., & Schmid, M. C. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037259 · Cited by 94
Zou, B., Liu, X., Zhang, B., Gong, Y., Cai, C., Li, P., Chen, J., Xing, S., Chen, J., Peng, S., et al. (2018) · Journal of Cancer · doi:10.7150/jca.25775 · Cited by 87
Li, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 94
“the efficacy of ICIs Failure of monotherapy makes people realize that the use of a single ICI cannot change the immunosuppressive TME of PDAC [107].”
BackgroundCancer‐associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets
Menezes, S., Okail, M. H., Jalil, S. M. A., Kocher, H. M., & Cameron, A. J. M. (2022) · The Journal of Pathology · doi:10.1002/path.5926 · Cited by 91
The role of stromal cells in the persistence of chronic inflammation
Naylor, A. J., Filer, A. D., & Buckley, C. D. (2012) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2012.04634.x · Cited by 93
Chung, K., Hsu, S., Chu, Y.-R., Lin, M.-Y., Jiaang, W.-T., Chen, R., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088772 · Cited by 92
LAI, D., MA, L., & WANG, F. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1475 · Cited by 84
TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease
Zhang, Y., Wang, J., Sun, H., Xun, Z., He, Z., Zhao, Y., Qi, J., Sun, S., Yang, Q., Gu, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179472 · Cited by 85
Single-cell sequencing and its applications in head and neck cancer
Qi, Z., Barrett, T. F., Parikh, A. S., Tirosh, I., & Puram, S. V. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104441 · Cited by 88
mRNA in cancer immunotherapy: beyond a source of antigen
Hoecke, L. V., Verbeke, R., Dewitte, H., Lentacker, I., Vermaelen, K. Y., Breckpot, K., & Lint, S. V. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01329-3 · Cited by 89
“Selective targeting of CAFs, or more specifically the CAF-specific fibroblast activating protein (FAP), is capable of precipitating tumoral collapse in preclinical tumor models [105, 106].”
BackgroundRadiotherapy: An immune response modifier for immuno-oncology
Martino, M. D., Daviaud, C., & Vanpouille‐Box, C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101474 · Cited by 88
The Role of Cancer-Associated Fibroblasts in Ovarian Cancer
Zhang, M., Chen, Z., Wang, Y., Zhao, H., & Du, Y. (2022) · Cancers · doi:10.3390/cancers14112637 · Cited by 91
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 88
What is new in cancer-associated fibroblast biomarkers?
Zhao, Z., Li, T., Yuan, Y., & Zhu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01125-0 · Cited by 89
“The strategies include FAP antibodies [23–25], genetic deletion [26], pharmacological inhibition (PT630, PT-100) [27, 28], conditional ablation using diphtheria toxin [21] or FAP-PE38 [25], and novel Table 2 The role of CAFs labeled by cancer-restraining markers in various kinds of cancer”
MethodPrognostic stromal gene signatures in breast cancer
Winslow, S., Leandersson, K., Edsjö, A., & Larsson, C. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0530-2 · Cited by 90
“FAP has been identified as a prognostic marker in various cancer studies, including breast and lung cancer, and has been suggested to be a potential target in solid tumors [37-40].”
Mesenchymal stromal cells: a key player in ‘innate tolerance’?
Dazzi, F., Lopes, L. M., & Weng, L. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03621.x · Cited by 91
Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 109
Cheng, Y., Chen, X., Li, F., Yang, Z., Xiao, L., Xiang, B., Wang, X., Liu, D., Lin, P., Shi, J.-Y., et al. (2025) · Cell Discovery · doi:10.1038/s41421-024-00747-z · Cited by 85
Estrogen-mediated activation of fibroblasts and its effects on the fibroid cell proliferation
Luo, N., Guan, Q., Zheng, L., Qu, X. A., Dai, H., & Cheng, Z. (2013) · Translational research · doi:10.1016/j.trsl.2013.11.008 · Cited by 87
Park, S. Y., Kim, H. M., & Koo, J. S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3291-9 · Cited by 90
The application of the fibroblast activation protein α-targeted immunotherapy strategy
Jiang, G., Xu, W., Du, J., Zhang, K.-S., Zhang, Q.-G., Wang, X.-W., Liu, Z.-G., Liu, S., Xie, W., Liu, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8098 · Cited by 86
“Furthermore, when FAP α expression was inhibited, tumor shrinkage was seen accompanied by increased expression of IFN-γ and TNF-α, indicating the existence of immune suppression that was restricted to the FAP α+ cells [8].”
BackgroundZhang, J., Chen, L., Liu, X., Kammertoens, T., Blankenstein, T. J. F., & Qin, Z. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3022 · Cited by 87
Mesenchymal Stem Cell-Like Properties in Fibroblasts
Chang, Y., Li, H., & Guo, Z. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000363035 · Cited by 80
Manuel, E. R., Blache, C. A., Paquette, R., Kaltcheva, T. I., Ishizaki, H., Ellenhorn, J. D. I., Hensel, M., Metelitsa, L. S., & Diamond, D. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4676 · Cited by 83
Lifting the innate immune barriers to antitumor immunity
Rothlin, C. V., & Ghosh, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000695 · Cited by 88
Jia, J., Martin, T. A., Ye, L., & Jiang, W. G. (2014) · BMC Cell Biology · doi:10.1186/1471-2121-15-16 · Cited by 82
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.079 · Cited by 80
Pancreatic stellate cells: Aiding and abetting pancreatic cancer progression
Pothula, S. P., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2020) · Pancreatology · doi:10.1016/j.pan.2020.01.003 · Cited by 86
Identifying cancer-associated fibroblasts as emerging targets for hepatocellular carcinoma
Zhang, J., Gu, C., Song, Q., Zhu, M., Xu, Y., Xiao, M., & Zheng, W. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00488-y · Cited by 96
The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy
Bever, K. M., Sugar, E. A., Bigelow, E. O., Sharma, R. B., Laheru, D. A., Wolfgang, C. L., Jaffee, E. M., Anders, R. A., Jesus‐Acosta, A. D., & Zheng, L. (2014) · HPB · doi:10.1111/hpb.12334 · Cited by 81
Targeting stroma to treat cancers
Engels, B., Rowley, D. A., & Schreiber, H. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.008 · Cited by 74
Eckrich, J., Kugler, P., Buhr, C. R., Ernst, B. P., Mendler, S., Baumgart, J., Brieger, J., & Wiesmann, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-75660-y · Cited by 79
Zheng, H., Liu, H., Li, H., Dou, W., & Wang, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.744677 · Cited by 83
The Bone Microenvironment: a Fertile Soil for Tumor Growth
Buenrostro, D., Mulcrone, P. L., Owens, P., & Sterling, J. A. R. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0315-2 · Cited by 82
Watanabe, S., Noma, K., Ohara, T., Kashima, H., Sato, H., Kato, T., Urano, S., Katsube, R., Hashimoto, Y., Tazawa, H., et al. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1617566 · Cited by 84
Zhu, Y., Chen, S., Zeng, L., Liu, G., Jiang, W., Zhang, X., Chen, S., Guo, J., Jian, X., Ouyang, J., et al. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23150 · Cited by 78
Romano, V., Belviso, I., Venuta, A., Ruocco, M. R., Masone, S., Aliotta, F., Fiume, G., Montagnani, S., Avagliano, A., & Arcucci, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105283 · Cited by 83
“CAFs have been shown to play a pivotal role in the regulation of both the innate and the adaptive tumor immune response by releasing pro‐inflammatory and immunosuppressive factors in the TME [168,169].”
BackgroundBusuttil, R. A., George, J., Tothill, R. W., Ioculano, K., Kowalczyk, A., Mitchell, C., Lade, S., Tan, P., Haviv, I., & Boussioutas, A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3049 · Cited by 77
Khoury, T., Nagrale, V., Opyrchal, M., Peng, X., Wang, D., & Yao, S. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000466 · Cited by 77
Gunderson, A. J., Yamazaki, T., McCarty, K., Phillips, M., Alice, A., Bambina, S., Zebertavage, L., Friedman, D., Cottam, B., Newell, P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0211117 · Cited by 70
Sum, E., Rapp, M., Fröbel, P., Clech, M. L., Dürr, H., Giusti, A. M., Perro, M., Speziale, D., Kunz, L., Menietti, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4001 · Cited by 77
Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma
Galbo, P. M., Madsen, A. T., Liu, Y., Peng, M., Yao, W., Ciesielski, M. J., Fenstermaker, R. A., Graff, S., Montagna, C., Segall, J. E., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0493 · Cited by 80
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 80
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
Zhao, Y., Jia, Y., Wang, J., Chen, X., Han, J., Zhen, S., Yin, S., Lv, W., Fan, Y., Wang, J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01957-5 · Cited by 77
Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila
Zhu, Z., Huang, J., Zhang, Y., Hou, W., Chen, F., Mo, Y., & Zhang, Z. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114306 · Cited by 78
Fibrocytes: emerging effector cells in chronic inflammation
Peng, H., & Herzog, E. L. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.03.002 · Cited by 76
Effects of the fibroblast activation protein on the invasion and migration of gastric cancer
Wang, R., Zhang, L., Shan, L., Sun, W., Chai, C., Wu, H., Ibla, J. C., Wang, L., & Liu, J. (2013) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2013.10.008 · Cited by 81
Lee, E., Pandey, N. B., & Popel, A. S. (2015) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2015.2 · Cited by 81
Heat Shock Proteins, Autoimmunity, and Cancer Treatment
Calderwood, S. K., Stevenson, M. A., & Murshid, A. (2012) · Autoimmune Diseases · doi:10.1155/2012/486069 · Cited by 83
Park, C. K., Jung, W. H., & Koo, J. S. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3929-2 · Cited by 81
Guillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications
Šimková, A., Bušek, P., Šedo, A., & Konvalinka, J. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140409 · Cited by 81
Fokas, E., O’Neill, E., Gordon-Weeks, A. N., Mukherjee, S., McKenna, W. G., & Muschel, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.12.001 · Cited by 84
Seo, J., Kim, A., Shin, J.-Y., & Kim, Y. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-32855-8 · Cited by 79
Jena, B. C., Das, C. K., Bharadwaj, D., & Mandal, M. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188416 · Cited by 80
Toste, P. A., Nguyen, A. H., Kadera, B. E., Duong, M., Wu, N., Gawlas, I., Tran, L. M., Bikhchandani, M., Li, L., Patel, S. G., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0348 · Cited by 74
Adityan, S., Tran, M. A., Bhavsar, C., & Wu, S. Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.016 · Cited by 76
The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
Wu, Y., Zhang, C., Jiang, K., Werner, J., Bazhin, A. V., & D’Haese, J. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621937 · Cited by 71
“revealed that depletion of FAP-a cells in stroma induced the immune response-mediated tumor regression in a subcutaneous mouse model of PDAC (132).”
BackgroundTCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 80
Sharma, U., Medina-Saenz, K., Miller, P. C., Troness, B., Spartz, A. K., Sandoval-Leon, A. C., Parke, D. N., Seagroves, T. N., Lippman, M. E., & El‐Ashry, D. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06299-0 · Cited by 77
“Tumor cells undergo many genetic and epigenetic changes that allow them to escape as CTCs, and these changes are, in part, mediated by CAFs [17, 30, 31].”
BackgroundNedaeinia, R., Najafgholian, S., Salehi, R., Goli, M., Ranjbar, M., Nickho, H., Javanmard, S. H., Ferns, G. A., & Manian, M. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02146-5 · Cited by 77
“However, a major barrier to more readily treating cancer with therapeutic techniques is the absence of precise markers for CAFs.”
BackgroundGorchs, L., Hellevik, T., Bruun, J.-A., Camilio, K.-A., Al-Saad, S., Stuge, T.-B., & Martinez-Zubiaurre, I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00087 · Cited by 71
“(49), highlighted already some years ago the important role played by CAFs as crucial immunosuppressive cells, emphasizing the capacity of CAFs to influence immune polarization toward a permissive, tumor-promoting microenvironment (32, 49).”
BackgroundResultThe Role of Tumour Stroma in Colorectal Cancer Invasion and Metastasis
Conti, J. A., & Thomas, G. J. (2011) · Cancers · doi:10.3390/cancers3022160 · Cited by 82
“Using the CT26 murine CRC model, Kraman and colleagues showed that fibroblast activation protein-α (FAP)-expressing tumour fibroblasts suppressed the tumour-directed adaptive immune response [53].”
MethodChard, L. S., Maniati, E., Wang, P., Zhang, Z., Gao, D., Wang, J., Cao, F., Ahmed, J., Khouri, M. E., Hughes, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0464 · Cited by 76
Cancer-Associated Myeloid Regulatory Cells
Vlaeminck, Y. D., González-Rascón, A. A., Goyvaerts, C., & Breckpot, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00113 · Cited by 81
“For example, targeting endothelial cells using a VEGF inhibitor resulted in decreased numbers of intratumoral MDSCs, while the depletion of cancer-associated fibroblasts, which express many immunosuppressive molecules, showed impaired tumor growth (96, 117).”
BackgroundEmerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Cancer-Associated Fibroblasts and T Cells: From Mechanisms to Outcomes
Baker, A. T., Abuwarwar, M. H., Poly, L., Wilkins, S., & Fletcher, A. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001203 · Cited by 67
Yu, S., Wang, S., Wang, X., & Xu, X. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03518-8 · Cited by 78
Upadhrasta, S., & Zheng, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091472 · Cited by 73
Gui, J., Zahedi, F., Ortiz, A., Cho, C., Katlinski, K. V., Alicea-Torres, K. M., Li, J., Todd, L., Zhang, H., Beiting, D. P., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0064-0 · Cited by 74
Bienkowska, K., Hanley, C. J., & Thomas, G. J. (2021) · Frontiers in Oral Health · doi:10.3389/froh.2021.686337 · Cited by 76
“Depletion of fibroblast activation protein (FAP)-positive CAF in murine models has been shown to enhance anti-tumour immunity [111]; Duperret et al.”
BackgroundO'Malley, G., Heijltjes, M., Houston, A. M., Rani, S., Ritter, T., Egan, L. J., & Ryan, A. E. (2016) · Oncotarget · doi:10.18632/oncotarget.11354 · Cited by 71
“Kraman [51] Lewis lung carcinoma and pancreatic ductal adenocarcinoma Mouse tumour tissue FAP, α-SMA, Col I (Immunostaining) LLC – depletion of FAP+ cells induced necrosis of tumour cells.”
BackgroundPaulson, K. G., Lahman, M. C., Chapuis, A. G., & Brownell, I. (2019) · International Immunology · doi:10.1093/intimm/dxz012 · Cited by 75
Connecting the Metabolic and Immune Responses to Cancer
Flint, T. R., Fearon, D. T., & Janowitz, T. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.001 · Cited by 72
Self-citation
Metadata
- Authors
- Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T.
- Affiliations
- University of Cambridge (GB)
- Wellcome Trust Immunology Unit, Department of Medicine, University of Cambridge, Medical Research Council Centre, Hills Road, Cambridge CB2 2QH, UK.
- Cancer Research UK (GB)
- Corresponding author
- Kraman, Matthew
- Bambrough, Paul J.
- Arnold, James N.
- Fearon, Douglas T.
- ORCID
- Venue
- Science
- Published
- 2010-11-05
- Volume
- 330
- Issue
- 6005
- Pages
- 827-830
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2048253455
- Cited by
- 1,134
- References
- 30
- Citations by year
- 2026: 55 · 2025: 71 · 2024: 81 · 2023: 80 · 2022: 90 · 2021: 106 · 2020: 95 · 2019: 75 · 2018: 55 · 2017: 59 · 2016: 76 · 2015: 69 · 2014: 66 · 2013: 65 · 2012: 60
- FWCI
- 25.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Wellcome Trust
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fibroblast activation protein, tumor stroma, tumor microenvironment, antitumor immunity, immunosuppression, Lewis lung carcinoma, pancreatic ductal adenocarcinoma, interferon-gamma, TNF-α, transgenic mouse model
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Antigens, Neoplasm, Cell Survival, Immune Tolerance, Interferon-gamma, Membrane Proteins, Mice, Transgenic, Necrosis, Neoplasm Transplantation, Endopeptidases, Serine Endopeptidases, Tumor Necrosis Factor-alpha, Cell Hypoxia, Stromal Cells, Gelatinases, Carcinoma, Lewis Lung, Cancer Vaccines, Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.